Artrya Limited (AYA)

Overview

Artrya Limited is a pioneering medical technology entity rooted in the domain of artificial intelligence (AI), committed to the mission of improving cardiac care. Founded in 2018 and headquartered in West Perth, Australia, the company leverages advanced AI algorithms to facilitate the early detection of coronary artery disease (CAD), the leading cause of heart attacks. By integrating cutting-edge technology with healthcare, Artrya aims to revolutionize the approach to diagnosing heart conditions, ultimately aiming to save lives and enhance patient outcomes through innovation and technological advancement.

Products and Services

• Salix

  A forefront cloud-based software solution designed by Artrya Limited, Salix stands out as the company’s flagship product. Utilizing proprietary AI algorithms, Salix is engineered to transform the detection and diagnosis process of coronary artery disease. The software meticulously analyses images from coronary computed tomography angiography (CCTA), a non-invasive imaging test that helps visualize the heart's blood vessels, to automate the detection of coronary artery disease with enhanced efficiency and accuracy. This innovation not only promises to streamline workflow for healthcare providers but also significantly improves the diagnostic process, aiding in the early identification and treatment of patients at risk of CAD.